Aug 17, 2020
DelMar Announces Approval of Merger by Stockholders
Jun 22, 2020
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
Jun 10, 2020
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
Jun 04, 2020
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
Jun 01, 2020
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 13, 2020
DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates
May 05, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
Mar 26, 2020
DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension
Mar 04, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
Feb 13, 2020
DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates
Feb 05, 2020
DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020
Jan 29, 2020
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Nov 25, 2019
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM
Nov 05, 2019
DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083
Oct 29, 2019
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting
Oct 24, 2019
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
Oct 10, 2019
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time
Sep 11, 2019
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019
Sep 10, 2019
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates
Sep 09, 2019
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria